Publicaciones en colaboración con investigadores/as de Brigham and Women's Hospital (10)

2022

  1. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  2. Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis

    JACC: Cardiovascular Imaging, Vol. 15, Núm. 11, pp. 1883-1896

2021

  1. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis

    Journal of the American College of Cardiology, Vol. 77, Núm. 12, pp. 1503-1516

2020

  1. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers

    Open Heart, Vol. 7, Núm. 1

2018

  1. Recurrence of Pericardial Mesothelioma Affecting the Myocardium After Pericardial Resection

    Annals of Thoracic Surgery, Vol. 106, Núm. 5, pp. e243-e245

2017

  1. Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy

    Open Heart, Vol. 4, Núm. 2

2015

  1. Diltiazem treatment for pre-Clinical hypertrophic cardiomyopathy sarcomereMutation carriers: A pilot randomized trial to modify disease expression

    JACC: Heart Failure, Vol. 3, Núm. 2, pp. 180-188

2013

  1. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy

    Circulation: Cardiovascular Imaging, Vol. 6, Núm. 3, pp. 415-422

2010

  1. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy

    New England Journal of Medicine, Vol. 363, Núm. 6, pp. 552-563

2006

  1. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis

    Journal of the American College of Cardiology, Vol. 47, Núm. 7, pp. 1369-1378